Physician
Central Medical Services of Southern New Mexico
Central Medical Services of Southern New Mexico was paid $539K by Medicaid between Jan 2018 and Dec 2024, across 23 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
33Billing provider infoCENTRAL MEDICAL SERVICES OF SOUTHERN NEW MEXICO
LAS CRUCES, NM 88011
LAS CRUCES, NM 88011
33aNPI1215379284assigned 07/19/2013
33bProvider typeOccupational Medicine Physician
28Total paid$539K
24GClaims8,180
24DCodes billed23
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 318 | $18K | |
| 2019 | 210 | $13K | |
| 2020 | 616 | $25K | |
| 2021 | 344 | $11K | |
| 2022 | 138 | $6K | |
| 2023 | 134 | $14K | |
| 2024incomplete | 6,420 | $453K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 1,714 | 1,478 | $145K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 23% | 781 | 752 | $122K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 550 | 512 | $82K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 13% | 587 | 580 | $71K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 8.8% | 232 | 231 | $47K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.4% | 687 | 663 | $29K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.2% | 578 | 520 | $17K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 327 | 298 | $8K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.5% | 381 | 350 | $8K |
| 80061 | Lipid panel | <1% | 128 | 118 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 139 | 131 | $1K |
| 86328 | <1% | 35 | 35 | $1K |
11 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 72 | $850.30 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $553.28 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 29 | $543.48 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 235 | $449.36 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 96 | $233.08 |
| 81003 | <1% | 144 | $217.30 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 316 | $211.25 |
| 87807 | <1% | 13 | $189.63 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $148.80 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 12 | $2.86 |
| 3008F | 0% | 1,098 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUBIO, RICARDO (OWNER)